<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220212054002N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-03-18</date_registration>
      <primary_sponsor>Mansoura university</primary_sponsor>
      <public_title>calcitonin in mastectomy pain</public_title>
      <acronym></acronym>
      <scientific_title>analgesic effect of adding calcitonin to bupivacaine in erector spine plane block for breast surgery ,double blind randomized study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>130</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61885</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: patients will randomly allocated to control group (A) and study group (B) with allocated ratio 1:1 .Randomization will done before surgery by computer generated random ,Version28.0 . Opaque sealed sequentially numbered envelopes containing the patients` codes will used and opened just before anethesia by physician who will not involved in the study A pharmacist will prepare the drug mixture. The patients will be allocated to either control group— group “A”, who receive only bupivacaine , or study group— group “B” who receive calcitonin plus bupivacaine in the ESP block with general anesthesia, Blinding description: participant ,care givers ,investigators all are blind to component of solution injected in unilateral erector spine plane block ,under ultrasound  after general anesthesia .As solution will be prepared by anesthesia technician in medication room before patient enter the operation room according to allocated randomized number .</study_design>
      <phase>4</phase>
      <hc_freetext>acute post mastectomy pain and post operative inflammatory reaction.</hc_freetext>
      <i_freetext>Intervention 1: control  group:  ultrasound guided  unilateral erector spine plane block will be performed under complete aseptic condition  after induction of general anesthesia directly and 15 min before skin incision with 100mm 21 G needle while the patient in unilateral position  ,60 patient in the group solution used for injection will be (30 ml bupivacaine 0.25% plus 2ml saline ). Intervention 2: Intervention group:  ultrasound guided  unilateral erector spine plane block will be performed under complete aseptic condition  after induction of general anesthesia directly and 15 min before skin incision with 100mm 21 G needle while the patient in unilateral position  ,60 patient in the group solution used for injection will be (30 ml bupivacaine 0.25% plus  50 IU calcitonin in 2ml saline ).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
IPD collected for primary outcome

When:
available starting 6 month after publication

To whom:
people working in academic institutions

Conditions:
academic purpose

Where to obtain:
email address// zenatddd@gmail .com

How to obtain:
email address

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zenat Eldadamony Mohamed</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Algomhorria</address>
        <city>Mansoura</city>
        <country1>Egypt</country1>
        <zip>35516</zip>
        <telephone>+20 122 543 9066</telephone>
        <email>zenatddd@gmail.com</email>
        <affiliation>Mansoura University Hospital</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zenat Eldadamony Mohamed</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Algomhorria</address>
        <city>Mansoura</city>
        <country1>Egypt</country1>
        <zip>35516</zip>
        <telephone>+20 122 543 9066</telephone>
        <email>zenatddd@gmail.com</email>
        <affiliation>Mansoura University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Egypt</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Female patients 
Aged 18–65 years,
American Society of Anesthesiologists physical status I and II,
Undergoing unilateral breast cancer surgery (modified radical mastectomy, breast conservational surgery, simple mastectomy and axillary clearance)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>patient refusal,
history of bronchial asthma
spinal deformities,
coagulation disorders,
allergy to local anesthetics,
history of opioid usage for chronic pain
cognitive/psychiatric disorders
infection at the injection site</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G89.18</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other acute postprocedural pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>control  group:  ultrasound guided  unilateral erector spine plane block will be performed under complete aseptic condition  after induction of general anesthesia directly and 15 min before skin incision with 100mm 21 G needle while the patient in unilateral position  ,60 patient in the group solution used for injection will be (30 ml bupivacaine 0.25% plus 2ml saline )</i_keyword>
      <i_keyword>Intervention group:  ultrasound guided  unilateral erector spine plane block will be performed under complete aseptic condition  after induction of general anesthesia directly and 15 min before skin incision with 100mm 21 G needle while the patient in unilateral position  ,60 patient in the group solution used for injection will be (30 ml bupivacaine 0.25% plus  50 IU calcitonin in 2ml saline )</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Time to rescue analgesia (opioid) in post operative period. Timepoint: time point measured from the end of surgery to request of analgesic. Method of measurement: visual analogue scale to measure pain  assessment of pain if VAS  is more than 3  patient will receive  morphine 10 Mg  intramuscular and reassess after 30 min for pain relieve .</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Total opioid requirement. Timepoint: 24 hour post operative. Method of measurement: amount of drug prescribed amount of morphine consumption in Mg in 24 hour after the end of surgery.</sec_outcome>
      <sec_outcome>Inflammatory mediators (interleukin 6,interlokin 10, and  tumor necrotic factor. Timepoint: before intervention and 2hour post operative ,12 hour post operative , and 24 hour post operative. Method of measurement: lab kit to measure inflammatory mediators.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mansoura university</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-29</approval_date>
        <contact_name>Institutional Research  Board ,IRB</contact_name>
        <contact_address>Algomhorria street Mansoura Dakahalia Egypt</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
